Early statin therapy for acute coronary syndromes

Annals of Pharmacotherapy

Volumn 36, Issue 11, 2002, Pages 1749-1758

  de Denus, Simon ^a   Spinler, Sarah A ^a,b  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acute coronary syndromes; Hydroxymethylglutaryl coenzyme A inhibitors; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATIN;

ARTICLE; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME INHIBITION; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; LIPID BLOOD LEVEL; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; THROMBOCYTE AGGREGATION; UNSTABLE ANGINA PECTORIS;

ANIMALS; ANTI-INFECTIVE AGENTS; CORONARY DISEASE; FLUOROQUINOLONES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0036840808     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A413     Document Type: Article

References (83)

1. American Heart Association 2001 heart and stroke statistical update [cited 2001 Jul 8] (8 screens). Available from: URL:http://www.americanheart. org/statistics.
2. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-9.
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.
6. Shepard J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
7. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOP). Circulation 1998;97:1440-5.
8. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2000;36:970-1062.
9. Woods D. Established and emerging cardiovascular risk factors. Am Heart J 2001;141(2 suppl):S49-57.
10. Oss R. Atherosclerosis - An inflammatory disease. N Engl J Med 1999;340:115-26.
11. Orford JL, Selwyn AP, Ganz P, Popma JJ, Rogers C. The comparative pathobiology of atherosclerosis and restenosis. Am J Cardiol 2000;86 (suppl):6H-11H.
12. Braun M, Pietch P, Schror K, Baumann G, Felix SB. Cellular adhesion molecules on vascular smooth muscle cells. Cardiovasc Res 1999;41:395-401.
13. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease. N Engl J Med 1995;332:512-21.
14. Kadar A, Glasz T. Development of atherosclerosis and plaque biology. Cardiovasc Surg 2001;9:109-21.
15. Rabbani R, Topol EJ. Strategies to achieve coronary arterial plaque stabilization. Cardiovasc Res 1999;41:402-17.
16. Forrester JS. Role of plaque rupture in acute coronary syndromes. Am J Cardiol 2000;86(suppl):15J-23J.
17. Gustein DE, Valentin VF. Pathophysiology and clinical significance of atherosclerotic plaque rupture. Cardiovasc Res 1999;41:323-33.
18. Sotiriou CG, Cheng JW. Beneficial effects of statins in coronary artery disease - Beyond lowering cholesterol. Ann Pharmacother 2000;34:1432-9.
19. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-93.
20. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after coronary syndromes. The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial. Circulation 1999;99:3227-33.
21. John S, Delles C, Jacobi J, Schlaich MP, Schneider M, Schmitz G, et al. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol 2001;37:1351-8.
22. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur NK, et al. Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001;104:376-9.
23. Laufs U, Hilgers S, Ribaudo N, Bohm M, Nickenig G. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 2001;88:1306-7.
24. Kaesemeyer WH, Caldwell RB, Huang J, Calwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999;33:234-41.
25. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000;20:61-9.
26. Wilson SH, Simari RD, Best PJM, Peterson TE, Lerman LO, Aviram M, et al. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2001;21:122-8.
27. Williams JK, Sukhova GK, Herington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the wall of atherosclerotic monkeys. J Am Coll Cardiol 1998;31:684-91.
28. Gould KL, Martucci JP. Goldberg DI, Hess MJ, Edens RP, Latifi R, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. Circulation 1994;89:1530-8.
29. Weber C, Wolfgang E. Weber KSC, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997;30:1212-7.
30. Rothe G, Herr AS, Sthor J, Abletshauser C, Weidinger G, Schmitz G. A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease. Atherosclerosis 1999;144:251-61.
31. Crisby M, Nordin-Fredrikson GN, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques. Circulation 2001;103:926-33.
32. Murphy RT, Foley JB, Mulvihill N, Crean P, Walsh MJ. Impact of preexisting status use on adhesion molecule expression in patients presenting with acute coronary syndromes. Am J Cardiol 2001;87:446-8.
33. Blann AD, Gurney D, Hughes E, Buggins P, Silverman SH, Lip GYH. Influence of pravastatin on lipoproteins, and on endothelial, platelet, and inflammatory markers in subjects with peripheral artery disease. Am J Cardiol 2001;88:89-92.
34. Ferro D, Parrotto S, Basili S, Alessandri C, Violi F. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000;36:427-31.
35. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoro Y, Furukawa Y, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001;103:276-83.
36. Bustos C, Hernandez-Presa MA, Ortego M, Tunon J, Ortega L, Perez F, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998;32:3057-64.
37. Ridker PM, Rifai N, Pfeffer MA, Cacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;98:839-44.
38. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-5.
39. Collaborative overview of randomized trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106.
40. Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol 2000;35:1103-15.
41. Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to anticoagulant therapy: Heparin: A statement for healthcare professionals from the American Heart Association. Circulation 2001;103:2994-3018.
42. Lacoste L, Lam JYT, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Circulation 1995;92:3172-7.
43. Notarbartolo A, Davi G, Averna M, Barbagallo CM, Ganci A, Giammarresi C, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15:247-51.
44. Tannous M, Cheung R, Vignini A, Mutus B. Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects. Thromb Haemost 1999;82:1390-4.
45. Alfon J, Palazon P, Badimon RL. Effects of statins in thrombosis and aortic lesion development in a dyslipidemic rabbit model. Thromb Haemost 1999;81:822-7.
46. Puccetti L, Bruni F, Bova G, Cercignani M, Pompella G, Auteri A, et al. Role of platelets in tissue factor expression by monocytes in normal and hypercholesterolemic subjects. In vitro effect of cerivastatin. Int J Clin Lab Res 2000;30:147-56.
47. Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 2001;103:2248-53.
48. Porreca E, Di Febbo C, Amore C, Castelnuovo A, Baccante G, Donati MB, et al. Effect of lipid-lowering treatment on factor VII profile in hyperlipidemic patients. Thromb Haemost 2000;84:789-93.
49. Rosenson RS, Tangney CC. Antithrombotic properties of statins. JAMA 1998;279:1643-50.
50. Dangas G, Badimon JJ, Smith DA, Unger AH, Levine D, Shao JH, et al. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 1999;33:1294-304.
51. Song JC, White CM. Do HMG-CoA reductase inhibitors affect fibrinogen? Ann Pharmacother 2001;35:236-41.
52. Lowe G, Rumley A, Ford J, Shepherd J, Cobbe S, Macfarlane P, et al. Blood theology, cardiovascular risk factors, and cardiovascular disease: The West of Scotland coronary prevention study. Thromb Haemost 2000;84:553-8.
53. Ueda Y, Kitaze M, Komamura K, Minamino T, Asanuma H, Sato H, et al. Pravastatin restored the infarct size-limiting effect of ischemic preconditioning blunted by hypercholesterolemia in the rabbit model of myocardial infarction. J Am Coll Cardiol 1999;34:2120-5.
54. Bauerssachs J, Galuppo P, Fraccarollo D, Christ M. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001;104:982-5.
55. Arntz HR, Agrawal R, Wunderlich W, Schnitzer L, Stern R, Fischer F, et al. Beneficial effects of pravastatin (± cholestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). Am J Cardiol 2000;86:1293-8.
56. Walter DH, Fichtlscerer S, Britten MB, Auch-Schwelk W, Schachinger V, Zeither AM. Benefit of immediate initiation of statin therapy following successful coronary stent implantation in patients with stable and unstable angina pectoris and Q-wave acute myocardial infarction. Am J Cardiol 2002;89:1-6.
57. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001;285:430-6.
58. Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: An observational study. Lancet 2001;357:1063-8.
59. Heeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002;105:1446-52.
60. Cannon CP, McCabe CH, Bentley J, Braunwald E. Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes: Observations from OPUS-TIM1 16 (abstract). J Am Coll Cardiol 2001;87(suppl A):334A.
61. McGuire DK, Kristinsson A, Bkapkar MV, Aylward PE, Verheugt FWA, Weaver WD, et al. Early statin use after acute coronary syndromes and outcomes at 90 days (abstract). Circulation 2001;104(suppl II):II-343.
62. Schiele R, Gitt AK, Heer T, Wienbergen H, Gieseler U, Glunz HG, et al. Early statin use in acute myocardial infarction is associated with a reduced hospital mortality: Results of MITRA-2 (abstract). Circulation 2000;18(suppl II):II-435.
63. Bybee KA, Wright RS, Williams BA, Grill JP, Kopecky SL. Is use of a statin agent at the time of presentation for acute myocardial infarction associated with a favorable outcome? (abstract). J Am Coll Cardiol 2000;35(suppl 1):314A.
64. Bybee KA, Wright RS, Powell BD, Williams BA, Vinar JT. Differential benefit from treatment with a statin agent at hospital discharge in non-ST elevation MI compared to ST elevation MI (abstract). Circulation 2000;18(suppl II):II-614.
65. Inhibition of platelet glycoprotein IIb/IIIA with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998;339:436-43.
66. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries. GUSTO IIb investigators. N Engl J Med 1996;335:775-82.
67. A comparison of aspirin plus tirofiban with aspirin plus heparin in unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998;338:1498-1505.
68. Cannon CP, McCabe CH, Wilcox RG, Langer A, Caspi A, Berink P, et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000; 102:149-56.
69. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. Lancet 2000;355:337-45.
70. Second SYMPHONY investigators. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation 2001;103:1727-33.
71. Liem A, van Boven AJ, Withagen AP, Robles de Medina RM, Veeger NJGM, Tijssen JGP. Fluvastatin in acute myocardial infarction: Effects on early and late ischemia and events: The FLORIDA trial (abstract). Circulation 2000;102:2672-d.
72. Schwartz GG, Oliver MF, Ezekowitz MD, Ganz P, Waters D, Kane JP, et al. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol 1998;81:578-81.
73. Schwartz GG, Olsson AG. Ezekowitz MD, Ganz P, Olivier MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled trial. JAMA 2001;285:1711-8.
74. Di Garbo V, Bobo M, Di Raimonto D, De Simone R, Asvellone G. Nonlipid, dose-dependent effects of pravastatin treatment on homeostatic system and inflammatory response. Eur J Clin Pharmacol 2000;56:277-84.
75. Gotto AM. Ongoing clinical trials of statins. Am J Cardiol 2001;88(suppl):36F-40F.
76. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
77. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-87.
78. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz LS, Title LM, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999;341:70-6.
79. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomized, double-blind trial. Lancet 2001;357:577-81.
80. Waters DD, Hsue PY, What is the role of intensive cholesterol lowering in the treatment of acute coronary syndromes? Am J Cardiol 2001; 88(suppl):7J-16J.
81. Tran MH, Schwartz G, Ganz P, Waters D, Arikian S. A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes (abstract). Circulation 2001;104(suppl II):II-798.
82. Feely J. The therapeutic gap. Compliance with medication and guidelines. Atherosclerosis 1999;47(suppl 1):S39-44.
83. Muhlestein JB, Horne BD, Bair TL, Li Q, Madsen TE, Pearson RR, et al. Usefulness of in-hospital prescription of statin agents after anglographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001;87:257-61.